NMN (nicotinamide mononucleotide): what it is, longevity, and whether it's worth supplementing after 40

NMN, or nicotinamide beta-mononucleotide, is marketed as a molecule that reverses the biological clock. When this message is compared with publications, the picture becomes much more modest. The most impressive results, from rejuvenated blood vessels to restored fertility, come from studies on mice. Human studies involve dozens of participants, last from two weeks to half a year, and primarily measure NAD+ levels in the blood, not lifespan. Additionally, there is a fact that sellers remain silent about: in the European Union, NMN does not have authorization as a novel food. Below you will find what was studied, how many participants were involved, who paid for it, and what the legal status is as of August 2026.

KEY INFORMATION
• A meta-analysis of 8 studies involving 342 adults found no improvement in glycemia, insulin, or lipids (Current Diabetes Reports, 2024).
• Rejuvenation of blood vessels, fertility, and endurance has been described in mice, not in humans.
• The largest human study involved 80 participants and lasted 60 days.
• In the EU, NMN is not authorized as a novel food.

What is NAD+ and why does its level decrease with age?

NAD+ is a coenzyme present in every cell. It carries electrons in cellular respiration and is consumed by DNA repair enzymes from the PARP family and by sirtuins, which are deacylases regulating gene expression. The body does not absorb NAD+ from food in its ready form but builds it from precursors.

There are several synthesis pathways. The first starts from tryptophan, the second from niacin, and the third is a salvage pathway in which nicotinamide returns to circulation thanks to the enzymes NAMPT and NMNAT. NMN is an intermediate product of this third pathway, just before NAD+ itself.

The decline with age is explained by increasing PARP activity, decreasing expression of synthesis enzymes, and greater activity of the enzyme CD38, which breaks down NAD+. The most frequently cited measurement in humans is the work Massudi i wsp. (PLoS ONE, 2012): 49 samples of human skin from individuals aged from newborn to 77 years, in which NAD+ levels decreased with age (in men after puberty r = -0.71, p = 0.0001, n = 19).

We noticed something worth stating directly. The repeated claim in product descriptions that "50% less NAD+ between the ages of 20 and 60" does not come from any measurement in living humans in that age range. It is a rounding derived from correlations measured on skin samples and on rodents. The direction of change is well documented, but the specific percentage is a marketing interpretation.

How does NMN differ from NR and from niacinamide?

These are three different molecules entering the same pathway at different points. Niacinamide (nicotinamide) is a form of vitamin B3, the cheapest and best-known. Nicotinamide riboside (NR) is formed from it by adding a sugar. NMN is NR with an added phosphate group, making it the last stop before NAD+.

Manufacturers like to argue that NMN is "closer" to NAD+, so it must work better. Biochemistry is less convenient here. A molecule with a phosphate group passes through the cell membrane less effectively, and the dispute over the transporter continues to this day. The team Grozio i wsp. (Nature Metabolism, 2019) described the protein Slc12a8 as an NMN transporter in the small intestine of mice. In the same journal, a response from Schmidt and Brenner titled "Absence of evidence that Slc12a8 encodes a nicotinamide mononucleotide transporter" was published. Both sides of the dispute have ties to the industry: Brenner collaborates with an NR producer, while the authors of the Slc12a8 paper are linked to NMN producers.

The regulator approached this without emotion. In assessing synthetic beta-NMN, the EFSA panel treated it simply as a source of nicotinamide and accepted a conversion factor of 1, meaning 300 mg of NMN corresponds to 109.7 mg of nicotinamide. From a nutritional assessment perspective, NMN thus provides vitamin B3 in a roundabout and significantly more expensive way.

What did NMN studies on mice show?

Almost everything that impresses in NMN advertisements has been measured on rodents. This is not a criticism of these studies, but rather information about the stage we are at. Mice live for about two years, so experiments on aging can be completed in a matter of months. In humans, such an experiment would take decades, and no one has conducted it so far.

Podstawowa praca to Mills i wsp. (Cell Metabolism, 2016): C57BL/6N mice were given NMN in water for 12 months. The animals gained less weight with age, had better energy metabolism, higher insulin sensitivity, and improved eyesight. It is worth noting what this study did not show: it did not measure an extension of the animals' lifespan.

Two other cited results also come from rodents. Das i wsp. (Cell, 2018) showed in old mice the restoration of capillary density and improved running endurance after administering NAD+ precursors. Bertoldo i wsp. (Cell Reports, 2020) described in aging female mice an improvement in egg cell quality and a partial restoration of fertility after administering NMN.

Translating these results to humans hinges on two things: the doses calculated per body mass are many times higher in mice, and laboratory animals live under controlled conditions. Thus, the result from a rodent is a hypothesis to be tested, not a promise of an effect in a forty-year-old.

How many people participated in NMN studies in humans?

Fewer than suggested by the market scale. The largest published trial involved 80 people, and a typical one ranges from a dozen to several dozen participants. The endpoints are usually NAD+ concentration in the blood or a simple fitness test, never lifespan. Below is a summary of the studies most frequently cited in product descriptions.

What do meta-analyses of these studies show together?

When summing individual trials, enthusiasm clearly wanes. A meta-analysis published in Current Diabetes Reports (2024) included 8 randomized studies and 342 adults who took between 250 and 2000 mg of NMN daily for periods ranging from 14 days to 12 weeks. No improvement in fasting glucose, insulin, glycated hemoglobin, HOMA-IR index, or lipid profile was found.

Physical fitness fared similarly. The meta-analysis in Journal of Cachexia, Sarcopenia and Muscle (2025) gathered studies on NMN and NR in individuals aged 60.9 to 83 years. Neither muscle mass, grip strength, nor walking speed improved significantly. The authors' conclusion is clear: the available data do not justify the use of both precursors in preventing sarcopenia.

One signal survived. A meta-analysis of 10 studies involving 349 individuals published in Nutrients (2026) showed a slight reduction in diastolic blood pressure, averaging 2.15 mmHg (95% CI from -3.68 to -0.61). Systolic pressure decreased only in the subgroup of individuals over 60 years old, by 3.94 mmHg. This is a real result, but the scale corresponds more to a reduction in dietary salt than to a hypotensive drug, and the authors themselves describe it as preliminary.

Is NMN legally sold in Poland as a supplement?

No. NMN is considered a novel food in the European Union under Regulation (EU) 2015/2283, and novel foods cannot be marketed as food or as a dietary supplement ingredient without authorization. This applies to the entire Union, including Poland.

The basis is formal. In the consultation regarding the status conducted under Article 4 of this regulation, with the Czech Republic as the assessing state, it was stated that NMN has not been shown to be consumed in the Union before May 15, 1997. The ingredient was classified into category 3(2)(a)(i), meaning a substance requiring authorization before being placed on the market.

In May 2026, the EFSA panel issued a positive opinion on the safety of synthetic beta-NMN, assessing it as a source of niacin in supplements up to 300 mg per day for adults, excluding pregnant and breastfeeding women. The application was submitted by EffePharm. The EFSA opinion is not an authorization. Only an implementing regulation from the European Commission places the ingredient on the EU list, and as of August 2026, there is no such entry for NMN. Authorization will also be subject to the protection of the applicant's data.

In the United States, the situation has changed twice. In 2022, the FDA excluded NMN from the definition of a dietary supplement because it had previously been allowed for research as a drug. In correspondence dated September 29, 2025, responding to industry petitions, the agency reversed this position and recognized that NMN is not excluded. The ingredient still requires notification as a new dietary ingredient there. So if you come across a store claiming that "in Poland and the EU NMN is a legal supplement,” you are dealing with a transfer of the American situation to the European context.

What is known about the safety of NMN and the quality of preparations?

In the short term, the profile looks calm. A meta-analysis of 15 studies published in Nutrients (2026), covering doses from 250 to 2000 mg per day and durations from 14 days to 24 weeks, did not show an increase in adverse events, discontinuations due to side effects, or elevated ALT and AST activity. Reported complaints mainly involve mild stomach discomfort.

However, the boundary of knowledge is clear. The longest study lasted 24 weeks, so nothing is known about use for a year or five years. In the EFSA assessment, a 90-day study on rats showed changes in reproductive organs, based on which the NOAEL was set at 400 mg per kilogram of body weight and an exposure margin of 93. Pregnant and breastfeeding women were excluded from the assessment.

A separate issue is the content of the packaging. A team from Singapore tested commercially available NMN and urolithin A preparations, comparing the actual amount of the substance with the declaration on the label. Deviations ranged from +28.6% to -100%, with the latter value indicating a product with no detectable active substance (Sandalova i wsp., GeroScience 2024). With an ingredient that has no authorization in the EU, there isn't even an office that would withdraw such a batch.

Which interventions have stronger evidence for slowing aging?

Much stronger evidence than any NAD+ precursor comes from boring and inexpensive things. Regular endurance and strength exercise, blood pressure control, not smoking, maintaining a regular sleep schedule, and keeping body weight within a reasonable range. These interventions have been studied on tens of thousands of people over decades, not on a few dozen volunteers for two months.

This order has practical significance. If the health budget is limited, spending it first on NMN and only then on sleep and activity is a reversal of priorities. A supplement with uncertain legal status and results measured in weeks will not replace a change whose effect is visible in population data. This is especially true for those over forty, where the first deviations in blood pressure and glycemia can still be reversed by lifestyle alone.

If you are still interested in this category, it is worth first getting to know ingredients with better-described effects. On our blog, you can read about koenzymie Q10 po czterdziestce, about resveratrol and its real impact on aging oraz o ingredients associated with longevity. A comparison of the precursors themselves can be found in the post NAD+ a NMN.

Frequently Asked Questions

Does NMN extend life in humans?

There is no evidence for that. No published study in humans has measured lifespan or aging rate, as the longest lasted 24 weeks. Results regarding longevity come from rodents, and mice live for about two years, so such an experiment can be concluded within a few months.

Jakie dawki NMN stosowano w badaniach u ludzi?

In published studies, doses ranged from 250 to 2000 mg daily for periods from 14 days to 24 weeks. The most commonly repeated protocol is 250 mg daily, used by Yoshino et al. (2021) and Igarashi et al. (2022). This is a description of what was studied, not a dosage recommendation.

Can NMN be legally purchased in Poland as a dietary supplement?

No. NMN is considered a novel food in the European Union under regulation 2015/2283 and does not have authorization, so it cannot be marketed as food or as an ingredient in dietary supplements. EFSA issued a positive safety opinion in May 2026, but this opinion does not replace authorization from the European Commission.

NMN or NR: which precursor has more data?

Nicotinamide riboside (NR) has been studied longer and has the status of authorized novel food in the EU, which NMN does not have. However, a meta-analysis from 2025 in the Journal of Cachexia, Sarcopenia and Muscle did not show any benefits from either for muscle mass or strength in people over 60.

Is NMN safe?

In the short term, it looks good. A meta-analysis of 15 studies, covering doses from 250 to 2000 mg per day and durations from 14 days to 24 weeks, did not show an increase in adverse events or increases in ALT and AST. There is no data beyond 24 weeks, and EFSA excluded pregnant and breastfeeding women from the assessment.

Who should not use NMN?

Pregnant and breastfeeding women, as they were excluded from the EFSA safety assessment. Caution also applies to individuals taking medications regularly and cancer patients, as the effect of increasing NAD+ on the metabolism of cancer cells has not been studied in humans. Discuss the decision with your doctor.

At u Bucha, we do not carry NMN preparations. If you are looking for products with regulated status, check the category supplements.

This article is for informational and educational purposes and does not constitute medical advice. Before starting supplementation, consult your doctor, especially if you are taking medications regularly, are pregnant or breastfeeding, or have a chronic illness.

Author: Michał Waluk · Opublikowano: 2026-06-22 · Aktualizacja: 2026-08-08